

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT : Jackowski et al.
INVENTION : Complement C3 Precursor Biopolymer
Markers Indicative of Alzheimers
Disease
SERIAL NUMBER : 09/994,909
FILING DATE : November 23, 2001
EXAMINER : Chernyshev, Olga N.
GROUP ART UNIT : 1646
OUR FILE NO. : 2132.090

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being
deposited with the U.S. Postal Service as First Class mail
in an envelope addressed to Commissioner for Patents
P.O. Box 1450, Alexandria, VA 22313-1450 on 11/29/2003

Mail Stop: Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

DECLARATION UNDER 37 CFR § 1.132

I, Dr. George Jackowski, do hereby declare as follows:

1. I am Chief Executive Officer and Chief Science Officer of
Syn-x Pharma Inc., assignee in the application entitled "Complement
C3 Precursor Biopolymer Markers Indicative of Alzheimers Disease",
having U.S. Application Serial No. 09/994,909 filed November 23,
2001.

2. In the Office Action mailed on July 29, 2003, claims 1 and
2 (as originally presented) were rejected under 35 U.S.C. 112, first
paragraph because the claimed invention allegedly contains subject

matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. The Examiner states that the invention is drawn to a biopolymer marker of SEQ ID NO:1 useful for indicating at least one particular disease state, for example, Alzheimers disease. The Examiner asserts that the experiments disclosed in the specification do not sufficiently support that the claimed peptide is a biopolymer marker of Alzheimers disease. The Examiner is particularly concerned with an alleged lack of controls in the experiments.

3. This declaration is submitted in order to clarify the use of controls in the experiments disclosed in the specification.

4. There are no conventional controls applied in the methods of the instant invention. Both samples from diseased patients and samples from healthy patients are separated by polyacrylamide gel electrophoresis. The gel is then examined in order to identify differences in the bands appearing in diseased and healthy patients. The bands, which differ between healthy and diseased patients, are excised and purified from the gel. A determination of up-regulation, down-regulation, presence and/or absence of the proteins present in the bands is assessed by sample wherein they appear, for example, the claimed peptide fragment was identified and excised from a band which appeared to be weakly expressed in the diseased samples as compared to the age-matched samples, thus this can be considered to be down-regulation of the protein in the

03/12/2004 FRI 14:53 FAX 561 625 6572 MCHALE & SLAVIN PA

036/038

Oct 29 2003 3:15PM Sy Pharma Inc
10/29/2003 WED 12:35 FAX

4' '989909


p.2

004/004

disease samples as compared to the increased presence of the protein in the age-matched samples. This comparison between two physiological states as evidenced by the bands appearing on the gel represents an inherent control in the experiment. The claimed protein fragment excised from the gel was sequenced and identified through the application of mass spectrometric techniques. It is standard laboratory practice to sequence peptides by mass spectrometry and identify the peptides based upon known sequences available in databases; without sequencing and comparing control peptides. One of ordinary skill in the art would be familiar with these standard protocols of mass spectrometry.

The undersigned declares that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the Application or any patent issuing thereon.

Oct 29 2003
Date


George Jackowski

\\MSZ\DRV E\STAMP DATA FILES\Ferris Lander's Files\FL\AMENDMENT.PAT\2132_050_132.wpd

McHale & Slavin P.A. 2132-090 -Declaration 37 CFR 1.132 Page 3 of 3